Join to View Full Profile
333 E 46th St12dNew York, NY 10017
Phone+1 203-988-5778
Are you Dr. Cassino?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Cara Cassino, MD is a pulmonologist in New York, New York. She is currently licensed to practice medicine in New York and Connecticut.
Education & Training
NYU Grossman School of MedicineFellowship, Pulmonary Disease and Critical Care Medicine, 1993 - 1994
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Pulmonary Disease and Critical Care Medicine, 1992 - 1993- NYU Grossman School of MedicineResidency, Internal Medicine, 1988 - 1991
- New York University School of MedicineClass of 1987
Certifications & Licensure
NY State Medical License 1989 - 2027
CT State Medical License 2002 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- 6 citationsExebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-D...Vance G Fowler Jr, Anita F Das, Joy Lipka-Diamond, Jane E Ambler, Raymond Schuch
Clinical Infectious Diseases. 2024-06-14 - 1 citationsIn vitro activity of exebacase against methicillin-resistant Staphylococcus aureus biofilms on orthopedic Kirschner wires.Melissa J Karau, Jay Mandrekar, Dario Lehoux, Raymond Schuch, Cara Cassino
BMC Research Notes. 2023-09-11 - 5 citationsSafety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection.Ganga S Moorthy, Rachel G Greenberg, Chi D Hornik, Cara Cassino, Parviz Ghahramani
Clinical Infectious Diseases. 2022-08-25
Press Mentions
ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateAugust 15th, 2022- CF-370 Reduces Hard-to-Treat Bacteria in Rabbit ModelMay 2nd, 2022
- ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent in Vivo Antimicrobial ActivityJuly 19th, 2021
- Join now to see all
